- Home
- LOOP vs ANVS Comparison
LOOP vs ANVS Comparison
Compare LOOP & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LOOP | ANVS |
|---|---|---|
| Founded | 2010 | 2008 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.7M | 69.1M |
| IPO Year | 2010 | 2019 |
Fundamental Metrics
Financial Performance| Metric | LOOP | ANVS |
|---|---|---|
| Price | $1.39 | $2.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | 47.4K | ★ 933.0K |
| Earning Date | 05-28-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 27.27 | ★ 39.39 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $10,889,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $174.82 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7016.99 | N/A |
| 52 Week Low | $0.88 | $1.54 |
| 52 Week High | $2.29 | $5.50 |
Technical Indicators
Market Signals| Indicator | LOOP | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 51.42 | 46.63 |
| Support Level | $1.20 | $1.86 |
| Resistance Level | $1.50 | $2.57 |
| Average True Range (ATR) | 0.07 | 0.16 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 43.23 | 37.47 |
Price Performance
Historical ComparisonAbout LOOP Loop Industries Inc.
Loop Industries Inc. is a technology and licensing company whose mission is to accelerate the world's shift toward sustainable plastic and away from dependence on fossil fuels. The company owns patented and proprietary technology that depolymerizes no and low value waste PET plastic and polyester fiber, including plastic bottles and packaging, carpet and polyester textile of any color, transparency or condition, and even ocean plastics that have been degraded by the sun and salt, to its base building blocks.
About ANVS Annovis Bio Inc.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.